MA38170A1 - Nouveaux acides indanyloxydihydrobenzofuranylacétiques - Google Patents
Nouveaux acides indanyloxydihydrobenzofuranylacétiquesInfo
- Publication number
- MA38170A1 MA38170A1 MA38170A MA38170A MA38170A1 MA 38170 A1 MA38170 A1 MA 38170A1 MA 38170 A MA38170 A MA 38170A MA 38170 A MA38170 A MA 38170A MA 38170 A1 MA38170 A1 MA 38170A1
- Authority
- MA
- Morocco
- Prior art keywords
- new
- indanyloxydihydrobenzofuranylacetic acids
- receptor
- acids
- new indanyloxydihydrobenzofuranylacetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention porte sur des composés représentés par la formule générale (i), dans laquelle le groupe (het)ar est tel que défini dans la revendication 1, qui ont des propriétés pharmacologiques de valeur, en particulier qui se lient au récepteur gpr40 et modulent son activité. Les composés sont appropriés pour le traitement et la prévention de maladies qui peuvent être influencées par ce récepteur, telles que des maladies métaboliques, en particulier le diabète de type 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12194590 | 2012-11-28 | ||
PCT/EP2013/074386 WO2014082918A1 (fr) | 2012-11-28 | 2013-11-21 | Nouveaux acides indanyloxydihydrobenzofuranylacétiques |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38170A1 true MA38170A1 (fr) | 2016-09-30 |
MA38170B1 MA38170B1 (fr) | 2017-04-28 |
Family
ID=47257634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38170A MA38170B1 (fr) | 2012-11-28 | 2013-11-21 | Nouveaux acides indanyloxydihydrobenzofuranylacétiques |
Country Status (23)
Country | Link |
---|---|
US (1) | US8815864B2 (fr) |
EP (1) | EP2925748B1 (fr) |
JP (1) | JP5913752B2 (fr) |
KR (1) | KR20150088878A (fr) |
CN (1) | CN104822675A (fr) |
AP (1) | AP2015008364A0 (fr) |
AR (1) | AR093631A1 (fr) |
AU (1) | AU2013351377A1 (fr) |
BR (1) | BR112015009376A2 (fr) |
CA (1) | CA2889783A1 (fr) |
CL (1) | CL2015001256A1 (fr) |
EA (1) | EA201500574A1 (fr) |
HK (1) | HK1210144A1 (fr) |
IL (1) | IL238128A0 (fr) |
MA (1) | MA38170B1 (fr) |
MX (1) | MX2015006591A (fr) |
PE (1) | PE20150968A1 (fr) |
PH (1) | PH12015501116A1 (fr) |
SG (1) | SG11201503800QA (fr) |
TN (1) | TN2015000158A1 (fr) |
TW (1) | TW201439075A (fr) |
UY (1) | UY35156A (fr) |
WO (1) | WO2014082918A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140163025A1 (en) | 2012-12-07 | 2014-06-12 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
EP3043784B9 (fr) | 2013-09-09 | 2019-11-20 | Peloton Therapeutics, Inc. | Aryléthers et utilisations de ceux-ci |
IN2013MU03577A (fr) | 2013-11-14 | 2015-07-31 | Cadila Healthcare Ltd | |
CA2931085C (fr) | 2013-12-16 | 2021-10-19 | Peloton Therapeutics, Inc. | Analogues de sulfone cyclique et de sulfoximine et leurs utilisations |
TW201613878A (en) | 2014-07-09 | 2016-04-16 | Janssen Pharmaceutica Nv | Pyrazine GPR40 agonists for the treatment of type II diabetes |
US10807948B2 (en) | 2015-03-11 | 2020-10-20 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
EP3268362B1 (fr) | 2015-03-11 | 2021-10-20 | Peloton Therapeutics, Inc. | Pyridines substituées et leurs utilisations |
WO2016145032A1 (fr) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions utilisées pour traiter l'hypertension artérielle pulmonaire |
WO2016145045A1 (fr) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Compositions s'utilisant dans le traitement du glioblastome |
WO2016168510A1 (fr) | 2015-04-17 | 2016-10-20 | Peloton Therapeutics, Inc. | Thérapie combinée avec un inhibiteur de hif-2-alpha et un agent immunothérapeutique, et applications corresponantes |
JP7050792B2 (ja) | 2017-01-26 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
US10919859B2 (en) | 2017-01-26 | 2021-02-16 | Boehringer Ingelheim International Gmbh | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
EP3573959B1 (fr) | 2017-01-26 | 2021-07-28 | Boehringer Ingelheim International GmbH | Acides benzylaminopyrazinylcyclopropanecarboxyliques, compositions pharmaceutiques et utilisations associées |
JP7050791B2 (ja) | 2017-01-26 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
EP3580222B1 (fr) | 2017-02-08 | 2021-04-07 | Boehringer Ingelheim International GmbH | Acides indanylaminoazadihydrobenzofuranylacétiques, compositions pharmaceutiques pour le traitement du diabète |
CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
CN112041311B (zh) | 2018-04-19 | 2023-10-03 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
US20210276985A1 (en) * | 2018-10-16 | 2021-09-09 | Autifony Therapeutics Limited | Novel compounds |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
IL291985A (en) | 2019-10-07 | 2022-06-01 | Kallyope Inc | gpr119 agonists |
MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
EP4172162A1 (fr) | 2020-06-26 | 2023-05-03 | Kallyope, Inc. | Activateurs d'ampk |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
WO2007033002A1 (fr) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Acides propanoïques 3-substitués par un groupement 4-hydroxyphényle à conformation contrainte pouvant être employés dans le traitement de troubles métaboliques |
EP2743268A3 (fr) | 2006-06-27 | 2014-10-08 | Takeda Pharmaceutical Company Limited | Composés cycliques condensés comme modulateurs du recepteur GPR40 |
RU2011102560A (ru) | 2008-06-25 | 2012-07-27 | Дайити Санкио Компани, Лимитед (Jp) | Соединение карбоновой кислоты |
AR084050A1 (es) | 2010-12-01 | 2013-04-17 | Boehringer Ingelheim Int | Acidos indaniloxidihidrobenzofuranilaceticos |
-
2013
- 2013-11-21 AP AP2015008364A patent/AP2015008364A0/xx unknown
- 2013-11-21 CA CA2889783A patent/CA2889783A1/fr not_active Abandoned
- 2013-11-21 BR BR112015009376A patent/BR112015009376A2/pt not_active IP Right Cessation
- 2013-11-21 KR KR1020157017075A patent/KR20150088878A/ko not_active Application Discontinuation
- 2013-11-21 CN CN201380062232.3A patent/CN104822675A/zh active Pending
- 2013-11-21 EA EA201500574A patent/EA201500574A1/ru unknown
- 2013-11-21 EP EP13794906.1A patent/EP2925748B1/fr active Active
- 2013-11-21 JP JP2015543427A patent/JP5913752B2/ja active Active
- 2013-11-21 MX MX2015006591A patent/MX2015006591A/es unknown
- 2013-11-21 PE PE2015000689A patent/PE20150968A1/es not_active Application Discontinuation
- 2013-11-21 SG SG11201503800QA patent/SG11201503800QA/en unknown
- 2013-11-21 WO PCT/EP2013/074386 patent/WO2014082918A1/fr active Application Filing
- 2013-11-21 MA MA38170A patent/MA38170B1/fr unknown
- 2013-11-21 AU AU2013351377A patent/AU2013351377A1/en not_active Abandoned
- 2013-11-25 US US14/088,493 patent/US8815864B2/en active Active
- 2013-11-27 AR ARP130104372A patent/AR093631A1/es unknown
- 2013-11-27 TW TW102143328A patent/TW201439075A/zh unknown
- 2013-11-28 UY UY0001035156A patent/UY35156A/es unknown
-
2015
- 2015-04-02 IL IL238128A patent/IL238128A0/en unknown
- 2015-04-24 TN TNP2015000158A patent/TN2015000158A1/fr unknown
- 2015-05-11 CL CL2015001256A patent/CL2015001256A1/es unknown
- 2015-05-20 PH PH12015501116A patent/PH12015501116A1/en unknown
- 2015-11-03 HK HK15110811.9A patent/HK1210144A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014082918A1 (fr) | 2014-06-05 |
HK1210144A1 (en) | 2016-04-15 |
JP5913752B2 (ja) | 2016-04-27 |
CA2889783A1 (fr) | 2014-06-05 |
EP2925748B1 (fr) | 2017-01-11 |
AU2013351377A1 (en) | 2015-04-16 |
US20140148462A1 (en) | 2014-05-29 |
TW201439075A (zh) | 2014-10-16 |
TN2015000158A1 (en) | 2016-10-03 |
KR20150088878A (ko) | 2015-08-03 |
EA201500574A1 (ru) | 2015-11-30 |
PE20150968A1 (es) | 2015-07-09 |
CN104822675A (zh) | 2015-08-05 |
BR112015009376A2 (pt) | 2017-07-04 |
CL2015001256A1 (es) | 2015-07-24 |
SG11201503800QA (en) | 2015-06-29 |
US8815864B2 (en) | 2014-08-26 |
MX2015006591A (es) | 2015-08-05 |
MA38170B1 (fr) | 2017-04-28 |
EP2925748A1 (fr) | 2015-10-07 |
PH12015501116A1 (en) | 2015-08-10 |
IL238128A0 (en) | 2015-05-31 |
AR093631A1 (es) | 2015-06-17 |
AP2015008364A0 (en) | 2015-04-30 |
JP2016500089A (ja) | 2016-01-07 |
UY35156A (es) | 2014-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38170A1 (fr) | Nouveaux acides indanyloxydihydrobenzofuranylacétiques | |
MA20150065A1 (fr) | Nouveaux dérivés d'acide indanyloxydihydrobenzofurannylacétique et leur utilisation comme agonistes du récepteur gpr40 | |
MA34383B1 (fr) | Analogues de glucagon | |
MA34916B1 (fr) | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques | |
MA33428B1 (fr) | Agonistes du gpr119 | |
TN2009000324A1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides | |
MA30228B1 (fr) | Pipéridinoylpyrrolidines agonistes du récepteur de mélanocortine de type 4 | |
EA201171098A1 (ru) | 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина | |
MA32654B1 (fr) | Composés modulant sélectivement le récepteur cb2 | |
EA200602242A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
EA201190207A1 (ru) | Соединения для лечения метаболических расстройств | |
MA33242B1 (fr) | Composes pour le traitement de troubles metaboliques | |
EA200602243A1 (ru) | 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов | |
EA201190004A1 (ru) | Конденсированные имидазол карбоксамиды в качестве модуляторов trpv3 | |
EA201491213A1 (ru) | Антагонисты trpm8 | |
EA201390826A1 (ru) | ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA | |
DE602006019911D1 (de) | Mglur1-antagonisten als therapeutische wirkstoffe | |
EA200900783A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
MA38217A1 (fr) | Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2 | |
MA34175B1 (fr) | Anticorps anti-cxcr4 humanisés pour le traitement de cancer | |
EA200900330A1 (ru) | Аналоги 2-феноксипиримидинона | |
MA45843A (fr) | Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) | |
EA201190208A1 (ru) | Соединения для лечения метаболических расстройств | |
MX2011012669A (es) | Nuevos agonistas del receptor de glucocorticoides. | |
MA38410B1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine |